 AUSTIN, Texas--BUSINESS WIRE--Savara Inc. Nasdaq: SVRA, an orphan lung disease company, today provided an update on changes to the Companys pipeline, leadership, and business operations that are being taken to improve alignment of resources and increase our focus on Molgradex in aPAP and the Phase 3 IMPALA 2 trial. I am grateful for the opportunity to be a part of the Savara team, said Matt Pauls, Chairman and CEO, Savara. Over the last few months, we have moved decisively and with urge 